Status:
COMPLETED
A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This single arm study will assess the efficacy and safety of treatment with Xeloda plus standard pelvic radiotherapy in participants with locally advanced rectal cancer. Eligible participants will rec...
Eligibility Criteria
Inclusion
- adult patients, 18-80 years of age;
- rectal cancer;
- planned surgery, and likely to benefit from pre-operative combined chemo-radiotherapy;
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Exclusion
- previous radiotherapy or chemotherapy for colorectal cancer;
- clinically significant cardiovascular disease;
- significant gastric or small intestine disease;
- serious uncontrolled active infection
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00796718
Start Date
October 1 2008
End Date
August 1 2010
Last Update
August 25 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Banská Bystrica, Slovakia, 975 17
2
Bratislava, Slovakia, 833 10